NCT03100045View on ClinicalTrials.gov

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

October 6, 2021

Study Completion Date

October 6, 2021

Conditions
HPV-Related Anal Intraepithelial NeoplasiaAIN2/3ArtesunateAlternative TreatmentAnal DysplasiaPrecancerous ConditionsHuman Papilloma Virus
Interventions
DRUG

Artesunate Suppositories

Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia

Trial Locations (2)

21205

Johns Hopkins Hospital, Baltimore

53792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors
All Listed Sponsors
collaborator

Frantz Viral Therapeutics, LLC

INDUSTRY

collaborator

University of Wisconsin, Madison

OTHER

lead

Johns Hopkins University

OTHER

NCT03100045 - Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) | Biotech Hunter | Biotech Hunter